Treatment
Teplizumab clinical trials
We’re tracking 8 recruiting studies that include Teplizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07457580Recruiting
A real-world study of teplizumab for type 1 diabetes
This study looks at real-world outcomes in patients with type 1 diabetes who received teplizumab through managed access programs. It helps researchers understand how well the treatment works outside of a clinical trial setting.
LeuvenAges Any age - NCT07360080Recruiting
Long-Term Effects of Teplizumab in Real-World Care
This study follows people who have already received teplizumab (a treatment to delay type 1 diabetes) to see how they do over time. It aims to understand the long-term effects in routine care.
Atlanta, GeorgiaAges Any age - NCT07260110Recruiting
Study of teplizumab vs. no treatment in stage 2 type 1 diabetes
This study watches people with stage 2 type 1 diabetes who either get teplizumab or not, to compare their real-world experiences. It helps researchers learn how the drug affects daily life.
San Francisco, CaliforniaAges 8 years+ - NCT07216391RecruitingPhase 2
Trial to delay type 1 diabetes: teplizumab vs. ATG
This study compares two medicines (teplizumab and anti-thymocyte globulin) to see if they can delay the onset of type 1 diabetes in people who are at high risk but don't have symptoms yet. If you have certain diabetes-related antibodies in your blood, this trial might help keep full-blown diabetes away for longer.
Aurora, ColoradoAges 4–34 - NCT07088068RecruitingPhase 3
Teplizumab for newly diagnosed type 1 diabetes
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
Scottsdale, ArizonaAges 1–25 - NCT06791291RecruitingPhase 2
Teplizumab for Japanese with early-stage type 1 diabetes
This trial tests an experimental drug called teplizumab to see if it can slow down or stop type 1 diabetes from getting worse. It is for Japanese people aged 1 to 34 who have stage 2 type 1 diabetes (blood sugar is slightly abnormal but not yet full diabetes).
Ichikawa, ChibaAges 1–34 - NCT06481904Recruiting
Registry for stage 2 type 1 diabetes
This study tracks people with stage 2 type 1 diabetes to see how they do over time, either with or without treatment with a drug called TZIELD. It helps doctors learn more about the disease and the effects of this treatment.
Los Angeles, CaliforniaAges Any age - NCT06338553RecruitingEarly Phase 1
GLP-1 drug for early type 1 diabetes
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
Nashville, TennesseeAges 12–50
What Teplizumab is being studied for
Conditions with recruiting Teplizumab studies.
Common questions
- Are there clinical trials studying Teplizumab?
- Yes. Clin2 currently lists 8 recruiting studies that include Teplizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Teplizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Teplizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Teplizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.